Topics
Gliomas | Treatment | Targeted therapy | Tovorafenib
Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > Tovorafenib
Nysom K, Kilburn LB, Leary SES, Landi DB, de Vos-Kerkhof E,
Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson
AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S,
McCowage G, Hansford JR, Khuong-Quang DA, Gottardo NG, Hassall T,
Han JW, Yalon Oren M, Chi SN, Qiu J, Da Costa D, Govinda Raju S,
Manley P, Hargrave D.
Radiographic and
visual response to the type II RAF inhibitor tovorafenib in
children with relapsed/refractory optic pathway glioma in the
FIREFLY-1 trial.
Neuro
Oncol. 2024 Dec 19:noae274. doi:
10.1093/neuonc/noae274. PMID:
39700439. Observational study. ˍ
Ioannou M, Mehta S, Devkota A, Bagley SJ, Ozer BH, Romo CG, Welch
MR, Justin JT, Holdhoff M, Schreck KC.
Clinical
experience with tovorafenib in adults with treatment-refractory
high- and low-grade gliomas.
Neurooncol
Pract. 2025 Jul 18;12(6):1051-1057. doi:
10.1093/nop/npaf068. PMID:
41458920. Observational study˰
ˍ